Sci. STKE, 5 December 2006
Medicine Progesterone and Breast Cancer
Paula A. Kiberstis
Science, AAAS, Washington, DC 20005, USA
Mutations in the breast cancer susceptibility gene BRCA1 greatly increase a womans risk of developing breast and ovarian cancers. Why do these mutations predominantly affect hormone-responsive tissues when the mutant gene is widely expressed throughout the body? Poole et al. (see the news story by Marx) suggest that this tissue specificity is caused in part by BRCA1-mediated effects on signaling by the hormone progesterone. Mammary epithelial cells (MECs) of Brca-1/p53-deficient mice accumulated high levels of progesterone receptors, probably through defective degradation by the proteasome, and developed aberrant proliferation of the MECs. Treatment with the progesterone antagonist mifepristone (RU 486) prevented or delayed mammary tumor development in the mice.
A. J. Poole, Y. Li, Y. Kim, S.-C. J. Lin, W.-H. Lee, E. Y.-H. P. Lee, Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467-1470 (2006). [Abstract] [Full Text]
Citation: P. A. Kiberstis, Progesterone and Breast Cancer. Sci. STKE 2006, tw411 (2006).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882